BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32442617)

  • 1. LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence.
    Mitchell KG; Parra ER; Zhang J; Nelson DB; Corsini EM; Villalobos P; Moran CA; Skoulidis F; Wistuba II; Fujimoto J; Roth JA; Antonoff MB;
    Ann Thorac Surg; 2020 Oct; 110(4):1131-1138. PubMed ID: 32442617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
    Baptiste Oudart J; Garinet S; Leger C; Barlesi F; Mazières J; Jeannin G; Audigier-Valette C; Morot-Sibilot D; Langlais A; Amour E; Mathiot N; Birsen G; Blons H; Wislez M
    Lung Cancer; 2024 Apr; 190():107508. PubMed ID: 38428265
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
    Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
    [No Abstract]   [Full Text] [Related]  

  • 4. A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma.
    Chen L; Engel BE; Welsh EA; Yoder SJ; Brantley SG; Chen DT; Beg AA; Cao C; Kaye FJ; Haura EB; Schabath MB; Cress WD
    J Thorac Oncol; 2016 Jun; 11(6):838-49. PubMed ID: 26917230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells.
    Lee BB; Kim Y; Kim D; Cho EY; Han J; Kim HK; Shim YM; Kim DH
    J Cell Mol Med; 2019 Apr; 23(4):2872-2889. PubMed ID: 30710424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serine threonine kinase 11/liver kinase B1 mutation in sporadic scirrhous-type gastric cancer cells.
    Nishimura S; Yashiro M; Sera T; Yamamoto Y; Kushitani Y; Sugimoto A; Kushiyama S; Togano S; Kuroda K; Okuno T; Murakami Y; Ohira M
    Carcinogenesis; 2020 Nov; 41(11):1616-1623. PubMed ID: 32236518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
    Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
    Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
    Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
    Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Pons-Tostivint E; Lugat A; Fontenau JF; Denis MG; Bennouna J
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas.
    Tsai LH; Chen PM; Cheng YW; Chen CY; Sheu GT; Wu TC; Lee H
    Oncogene; 2014 Jul; 33(29):3851-60. PubMed ID: 23995788
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
    Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced expression of liver kinase B1 and Beclin1 is associated with the poor survival of patients with non-small cell lung cancer.
    Jiang L; Liang X; Liu M; Wang W; Ma J; Guo Q; Han L; Yang C; Nan K
    Oncol Rep; 2014 Nov; 32(5):1931-8. PubMed ID: 25175672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoplasmic liver kinase B1 promotes the growth of human lung adenocarcinoma by enhancing autophagy.
    Liu M; Jiang L; Fu X; Wang W; Ma J; Tian T; Nan K; Liang X
    Cancer Sci; 2018 Oct; 109(10):3055-3067. PubMed ID: 30033530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic correlations of liver kinase B1, E-cadherin, and N-cadherin expression in non-small cell lung cancer.
    Liu S; Miao Y; Fan C; Liu Y; Yu J; Zhang Y; Dai S; Wang E
    Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):334-40. PubMed ID: 23235348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer.
    Hasegawa T; Yanagitani N; Ninomiya H; Sakamoto H; Tozuka T; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Ariyasu R; Uchibori K; Kitazono S; Horiike A; Nishio M
    In Vivo; 2020; 34(5):2997-3003. PubMed ID: 32871843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AXL targeting restores PD-1 blockade sensitivity of
    Li H; Liu Z; Liu L; Zhang H; Han C; Girard L; Park H; Zhang A; Dong C; Ye J; Rayford A; Peyton M; Li X; Avila K; Cao X; Hu S; Alam MM; Akbay EA; Solis LM; Behrens C; Hernandez-Ruiz S; Lu W; Wistuba I; Heymach JV; Chisamore M; Micklem D; Gabra H; Gausdal G; Lorens JB; Li B; Fu YX; Minna JD; Brekken RA
    Cell Rep Med; 2022 Mar; 3(3):100554. PubMed ID: 35492873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Less immune cell infiltration and worse prognosis after immunotherapy for patients with lung adenocarcinoma who harbored STK11 mutation.
    Wang H; Guo J; Shang X; Wang Z
    Int Immunopharmacol; 2020 Jul; 84():106574. PubMed ID: 32413741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer.
    Best SA; Gubser PM; Sethumadhavan S; Kersbergen A; Negrón Abril YL; Goldford J; Sellers K; Abeysekera W; Garnham AL; McDonald JA; Weeden CE; Anderson D; Pirman D; Roddy TP; Creek DJ; Kallies A; Kingsbury G; Sutherland KD
    Cell Metab; 2022 Jun; 34(6):874-887.e6. PubMed ID: 35504291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases.
    Gleeson FC; Kipp BR; Levy MJ; Voss JS; Campion MB; Minot DM; Tu ZJ; Klee EW; Lazaridis KN; Kerr SE
    J Thorac Oncol; 2015 Mar; 10(3):531-4. PubMed ID: 25695224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic factors of recurrence and survival in female patients with lung adenocarcinoma and breast cancer.
    Chen YY; Huang YJ; Huang HK; Chang H; Lee SC; Shieh YS; Huang TW
    J Cancer Res Clin Oncol; 2020 May; 146(5):1299-1306. PubMed ID: 32107626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.